BrainsWay Ltd. (BWAY)
9.13
0.01 (0.11%)
At close: Apr 25, 2025, 3:59 PM
9.21
0.88%
After-hours: Apr 25, 2025, 04:05 PM EDT
Company Description
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally.
It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry.
Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BrainsWay Ltd.

Country | IL |
IPO Date | Apr 17, 2019 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 120 |
CEO | Hadar Levy |
Contact Details
Address: Bynet Building Jerusalem, IL | |
Website | https://www.brainsway.com |
Stock Details
Ticker Symbol | BWAY |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001505065 |
CUSIP Number | 10501L106 |
ISIN Number | US10501L1061 |
Employer ID | 00-0000000 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Hadar Levy | Chief Executive Officer |
Ido Marom | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 22, 2025 | F-3 | Filing |
Apr 22, 2025 | 20-F | Filing |
Mar 11, 2025 | 6-K | Filing |
Jan 28, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Dec 12, 2024 | 6-K | Filing |
Nov 20, 2024 | 6-K | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 13, 2024 | SC 13D | Filing |
Nov 05, 2024 | 6-K | Filing |